Nontuberculous Mycobacteria Market, By Infection Type (Pulmonary NTM Infections, Skin and soft tissue infections, Disseminated , Lymph node infections and Others), By Diagnosis Method, By Therapeutic Area, By End-Use, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5610
|
Published Date
July 2026
|
Pages
308
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Nontuberculous Mycobacteria Market size was valued at USD 9,830.1 Million in 2025, expanding to a CAGR of 3.8% from 2026 to 2033.
Nontuberculous mycobacteria (NTM) are a group of bacteria that are found in the environment, including soil, water, dust and in many natural and man-made environments. NTM infections are not usually spread from person to person, as is the case with the bacteria that cause tuberculosis or leprosy. You can be exposed to these bacteria through everyday activities such as breathing in contaminated particles, drinking or using contaminated water, or on contaminated surfaces.
Nontuberculous Mycobacteria Market- Market Dynamics
Growing prevalence of pulmonary, skin tissue infections and developments in targeted, diagnostic therapies are expected to propel market demand
A key factor supporting the growth of the Nontuberculous Mycobacteria (NTM) market is the rising number of diagnosed infections, including pulmonary, skin, soft tissue, and other forms of NTM disease across the world. An ageing population, an increasing incidence of chronic lung conditions and a larger population of people with weakened immune systems have increased the risk of developing these infections. A greater awareness among healthcare providers has also resulted in more screening and earlier diagnosis of diseases related to NTM. Advances in diagnostic technologies, particularly molecular and genetic testing methods, have made it easier to accurately identify NTM infections and differentiate them from other respiratory diseases. As more cases are detected and diagnosed, the demand for effective diagnostic tools, targeted treatment options, and ongoing patient management continues to grow, contributing significantly to the expansion of the global NTM market.
The other important factor propelling the NTM market is the continuous advancements in treatment and diagnostic capabilities. Previously, treatment of NTM infections often consisted of prolonged courses of antibiotics, sometimes for months or years, with mixed results. Now, pharmaceutical companies, biotech companies and research institutions are seeking to develop more targeted therapies, including new drug candidates and inhaled treatment options, to improve efficacy and patient adherence. At the same time, diagnostic technologies are becoming faster, more accurate, and better at identifying specific NTM species. This allows healthcare providers to make better treatment decisions sooner and customize therapies to the needs of each patient. The increasing adoption of personalized treatment approaches supported by advanced diagnostic testing is another major trend fueling market demand. For example, Insmed continued advancing its NTM treatment portfolio through the global Phase 3 ENCORE clinical trials in 2025. Thus, increased investment in infectious disease research, favorable regulatory initiatives, and stronger collaboration between industry and healthcare organizations are further encouraging innovation, creating new opportunities for growth in the global NTM market.
Nontuberculous Mycobacteria Market- Segmentation Analysis:
The Global Nontuberculous Mycobacteria Market is segmented on the basis of Infection Type, Diagnosis Method, Therapeutic Area, End-Use, and Region.
The market is divided into five categories based on Infection Type: pulmonary NTM Infections, skin and soft tissue infections, disseminated NTM infections, lymph node infections, and others. Pulmonary NTM infections segment accounted for a substantial share in the infection type. Growing prevalence of lung-related NTM diseases is increasing incidences of pulmonary infections. NTM organisms are usually inhaled from environmental sources such as soil particles, water aerosols, and dust, making the lungs the most frequently affected. Pulmonary infections require prolonged treatment and care.
Nontuberculous Mycobacteria Market- Geographical Insights
North America holds a vital position in the NTM market, driven by a combination of higher disease detection rates, well-established healthcare systems, and access to advanced diagnostic tools. The region has seen a steady increase in the identification of NTM-related lung diseases, particularly among older adults and individuals with chronic respiratory conditions. Strong investment in infectious disease research, ongoing clinical trials, and the presence of companies focused on developing NTM-specific therapies have further strengthened the market. In addition, greater awareness among physicians has contributed to earlier diagnosis and improved patient management, supporting continued market expansion. Europe also represents a substantial share of the market, supported by improvements in disease monitoring and growing recognition of NTM infections as a significant public health concern.
UK Nontuberculous Mycobacteria Market- Key Insights
The NTM market in the UK is growing at a significant rate as healthcare providers are increasingly focusing on the often-underdiagnosed infections. There is an increasing population exposed to NTM disease, particularly pulmonary infections, due to the increasing number of patients with chronic respiratory diseases such as bronchiectasis and COPD. This has led to the greater use of sophisticated diagnostic techniques and more comprehensive programs of respiratory care throughout the country. Improved evaluation, diagnosis and the long-term management of patients are playing an important part of specialized lung disease clinics and respiratory centers. At the same time, ongoing research initiatives and efforts to increase infectious disease monitoring are helping generate a better understanding of NTM prevalence and treatment challenges. Growing clinical awareness, combined with improved access to specialized diagnostic services and patient care pathways, is creating favorable conditions for continued expansion of the UK NTM market and reinforcing its importance within the broader European healthcare industry.
Nontuberculous Mycobacteria Market- Competitive Landscape:
The NTM market is becoming increasingly competitive as pharmaceutical companies, biotechnology firms, and diagnostic technology providers expand their efforts to improve the detection and treatment of NTM infections. For many years, patients had limited treatment options and often faced long, complex therapy regimens that did not always deliver consistent results. This has created significant opportunities for innovation, prompting companies to invest in new therapies and disease management solutions. Moreover, advances in diagnostic technologies are making it easier to identify specific NTM species with greater speed and accuracy. For example, Insmed strengthened its global market presence for ARIKAYCE by advancing commercialization efforts and continuing to invest in clinical research and regulatory initiatives in 2025. Its strategy focused on generating additional clinical data, improving patient access to treatment, and pursuing broader regulatory approvals to support expanded use of the therapy in NTM-related lung diseases.
Recent Developments:
- In March 2025, Spero Therapeutics advanced its review of the SPR720 Phase 2 program for NTM pulmonary disease, analyzing interim clinical results to guide upcoming developments plans.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET KEY PLAYERS
- Insmed Incorporated
- Spero Therapeutics
- Johnson & Johnson
- Pfizer
- AstraZeneca
- Hoffmann-La Roche Ltd.
- Merck & Co.
- Sanofi
- Bristol Myers Squibb
- Eli Lilly and Company
- Thermo Fisher Scientific
- QIAGEN
- bioMérieux
- Becton, Dickinson and Company (BD)
- Danaher Corporation
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2020-2033
- Pulmonary NTM Infections
- Skin and soft tissue infections
- Disseminated NTM infections
- Lymph node infections
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DIAGNOSIS METHOD- MARKET ANALYSIS, 2020-2033
- Molecular Diagnostics
- Imaging Testing
- Microscopy
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020-2033
- Antibiotic Therapy
- Combination Drug Therapy
- Surgical Intervention
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY END-USE- MARKET ANALYSIS, 2020-2033
- Hospitals & Specialty Clinics
- Diagnostic Laboratories
- Academic Research
- Ambulatory Surgical Centers
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY REGION- MARKET ANALYSIS, 2020-2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENT
1. Nontuberculous mycobacteria Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Nontuberculous mycobacteria Market Snippet by Infection Type
2.1.2. Nontuberculous mycobacteria Market Snippet by Diagnosis Method
2.1.3. Nontuberculous mycobacteria Market Snippet by Therapeutic Area
2.1.4. Nontuberculous mycobacteria Market Snippet by End-Use
2.1.5. Nontuberculous mycobacteria Market Snippet by Country
2.1.6. Nontuberculous mycobacteria Market Snippet by Region
2.2. Competitive Insights
3. Nontuberculous mycobacteria Key Market Trends
3.1. Nontuberculous mycobacteria Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Nontuberculous mycobacteria Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Nontuberculous mycobacteria Market Opportunities
3.4. Nontuberculous mycobacteria Market Future Trends
4. Nontuberculous mycobacteria Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Nontuberculous mycobacteria Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Nontuberculous mycobacteria Market Landscape
6.1. Nontuberculous mycobacteria Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Nontuberculous mycobacteria Market – By Infection Type
7.1. Overview
7.1.1. Segment Share Analysis, By Infection Type, 2025 & 2033 (%)
7.1.2. Pulmonary NTM Infections
7.1.3. Skin and soft tissue infections
7.1.4. Disseminated NTM infections
7.1.5. Lymph node infections
7.1.6. Others
8. Nontuberculous mycobacteria Market – By Diagnosis Method
8.1. Overview
8.1.1. Segment Share Analysis, By Diagnosis Method, 2025 & 2033 (%)
8.1.2. Molecular Diagnostics
8.1.3. Imaging Testing
8.1.4. Microscopy
8.1.5. Others
9. Nontuberculous mycobacteria Market – By Therapeutic Area
9.1. Overview
9.1.1. Segment Share Analysis, By Therapeutic Area, 2025 & 2033 (%)
9.1.2. Antibiotic Therapy
9.1.3. Combination Drug Therapy
9.1.4. Surgical Intervention
9.1.5. Others
10. Nontuberculous mycobacteria Market – By End-Use
10.1. Overview
10.1.1. Segment Share Analysis, By End-Use, 2025 & 2033 (%)
10.1.2. Hospitals & Specialty Clinics
10.1.3. Diagnostic Laboratories
10.1.4. Academic Research
10.1.5. Ambulatory Surgical Centers
10.1.6. Others
11. Nontuberculous mycobacteria Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Nontuberculous mycobacteria Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Nontuberculous mycobacteria Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Nontuberculous mycobacteria Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Nontuberculous mycobacteria Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Nontuberculous mycobacteria Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Infection Type, 2020 - 2033 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Diagnosis Method, 2020 - 2033 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End-Use, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Nontuberculous mycobacteria Industry
12.1. Competitive Dashboard
12.1.1. Competitive Benchmarking
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Insmed Incorporated
12.2.2. Spero Therapeutics
12.2.3. Johnson & Johnson
12.2.4. Pfizer
12.2.5. AstraZeneca
12.2.6. F. Hoffmann-La Roche Ltd.
12.2.7. Merck & Co.
12.2.8. Sanofi
12.2.9. Bristol Myers Squibb
12.2.10. Eli Lilly and Company
12.2.11. Thermo Fisher Scientific
12.2.12. QIAGEN
12.2.13. bioMérieux
12.2.14. Becton, Dickinson and Company (BD)
12.2.15. Danaher Corporation
12.2.16. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET KEY PLAYERS
- Insmed Incorporated
- Spero Therapeutics
- Johnson & Johnson
- Pfizer
- AstraZeneca
- Hoffmann-La Roche Ltd.
- Merck & Co.
- Sanofi
- Bristol Myers Squibb
- Eli Lilly and Company
- Thermo Fisher Scientific
- QIAGEN
- bioMérieux
- Becton, Dickinson and Company (BD)
- Danaher Corporation
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2020-2033
- Pulmonary NTM Infections
- Skin and soft tissue infections
- Disseminated NTM infections
- Lymph node infections
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DIAGNOSIS METHOD- MARKET ANALYSIS, 2020-2033
- Molecular Diagnostics
- Imaging Testing
- Microscopy
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020-2033
- Antibiotic Therapy
- Combination Drug Therapy
- Surgical Intervention
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY END-USE- MARKET ANALYSIS, 2020-2033
- Hospitals & Specialty Clinics
- Diagnostic Laboratories
- Academic Research
- Ambulatory Surgical Centers
- Others
GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY REGION- MARKET ANALYSIS, 2020-2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
